NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

中國的Docetaxel 市場分析 (2021年∼2025年)

Investigation Report on China's Docetaxel Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1009416
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
中國的Docetaxel 市場分析 (2021年∼2025年) Investigation Report on China's Docetaxel Market 2021-2025
出版日期: 2021年06月04日內容資訊: 英文 50 Pages
簡介

Docetaxel ,是局部進行性或轉移性的非小細胞肺癌的治療所使用的Paclitaxel抗癌藥物。中國1996年核可,至2020年有複數的廠商進入。Docetaxel 的銷售額從2016年到2019年持續擴大趨勢,不過,2020年由於新型冠狀病毒感染疾病 (COVID-19)的影響轉為縮小,成為了11億1200萬人民幣 (與前一年同期比較減少16.79%)。能認為今後,隨著COVID-19結束和癌症發病率的上升,市場規模回歸成長軌道。

本報告提供中國的Docetaxel 的市場相關分析,產品的概要和授權情形,整體市場規模趨勢預測 (2016年∼2020年/2021年∼2025年),各地區的詳細趨勢,市場價格趨勢預測,主要企業的簡介與市場佔有率,主要的推動及阻礙市場要素等彙整資訊,為您概述為以下內容。

目錄

第1章 Docetaxel 的相關概念

  • Docetaxel 的適應症
  • 中國國內的Docetaxel 的開發趨勢
  • 中國政府的Docetaxel 的核準情況
  • COVID-19對中國的Docetaxel 銷售的影響

第2章 中國國內的Docetaxel 銷售趨勢 (2016年∼2020年)

  • Docetaxel 的銷售額
    • 總銷售額
    • 各地區的銷售額
  • Docetaxel 的銷售量
    • 總銷售量
    • 各地區的銷售量
  • 中國國內的Docetaxel 銷售趨勢:各劑型 (2016年∼2020年)
    • 投入的藥劑
    • 其他的劑型

第3章 中國的Docetaxel 主要製造商分析 (2020年)

  • 主要Docetaxel 製造商市場佔有率分析
    • 市場佔有率:銷售額為基礎
    • 市場佔有率:銷售量為基礎
  • Aventis Pharma SA
    • 企業簡介
    • 中國的Docetaxel 銷售趨勢
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Shenzhen Wanle Pharmaceutical Co.,Ltd.
  • Sichuan Huiyu Pharmaceutical Co., Ltd.
  • Yangtze River Pharmaceutical Group Co.,Ltd.

第4章 中國的Docetaxel 的價格趨勢:各主要製造商 (2020年∼2021年)

  • Aventis Pharma SA (TAXOTERE)
  • Jiangsu Hengrui Medicine Co., Ltd. (Aisu)
  • Shenzhen Wanle Pharmaceutical Co., Ltd. (Xichun)
  • Sichuan Huiyu Pharmaceutical Co., Ltd. (Huiyu)
  • Yangtze River Pharmaceutical Group Co.,Ltd. (Tianlun)

第5章 中國的Docetaxel 市場未來展望 (2021年∼2025年)

  • 左右中國的Docetaxel 市場趨勢的要素
    • COVID-19對中國的Docetaxel 市場的影響
    • 市場促進因素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2106516

Docetaxel, sold under the brand name Taxotere, is a paclitaxel anti-tumor drug used for the treatment of locally advanced or metastatic non-small cell lung cancer. Docetaxel injection was first developed and produced by the French company Rhone Planck Lean (later renamed Aventis, also known as Sanofi-Aventis). It was first approved for marketing by the European Union in 1995 and approved in China in 1996. By 2020, there are several manufacturers in the Chinese Docetaxel market.

According to CRI's market research, the sales value of Docetaxel in the Chinese market remained constant from 2016 to 2019. Due to the impact of the COVID-19 epidemic on China's hospital's overall diagnosis and treatment services, the sales value of Docetaxel in the Chinese market decreased to CNY1.112 billion in 2020, a year-on-year decrease of 16.79%. The CAGR of the sales value of Docetaxel in the Chinese market from 2016 to 2020 was -3.86%.

CRI expects that with the alleviation of the COVID-19 epidemic, sales of Docetaxel will have a restorative growth from 2021 to 2025. In addition, 4.57 million new cancer cases were diagnosed in China in 2020, and the overall cancer incidence increased by about 3.9% annually. Therefore, the sales volume of Docetaxel for the treatment of locally advanced or metastatic non-small cell lung cancer will increase with the increase of colon cancer patients and there is room for sales to rise. At the same time, compared with similar drugs, Docetaxel is safer and more effective, the sales volume will grow in the future.

Topics Covered:

  • The impact of COVID-19 on China's Docetaxel market
  • Sales value of China's Docetaxel 2016-2020
  • Competitive landscape of China's Docetaxel market
  • Prices of Docetaxel in China
  • Prices of Docetaxel in China by regions and manufacturers
  • Analysis of factors affecting the development of China's Docetaxel market
  • Prospect of China's Docetaxel market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Docetaxel

  • 1.1 Indications for Docetaxel
  • 1.2 Development of Docetaxel in China
  • 1.3 Governmental Approval of Docetaxel in China
  • 1.4 The Impact of COVID-19 on Docetaxel Sales in China

2 Sales of Docetaxel in China, 2016-2020

  • 2.1 Sales Value of Docetaxel
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Docetaxel
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Docetaxel by Dosage Form in China, 2016-2020
    • 2.3.1 Injection
    • 2.3.2 Analysis of Other Dosage Form

3 Analysis of Major Docetaxel Manufacturers in China in 2020

  • 3.1 Analysis of Market Share of Major Docetaxel Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Aventis Pharma SA
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of TAXOTERE (Aventis Pharma SA's Docetaxel) in China
  • 3.3 Jiangsu Hengrui Medicine Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Aisu (Jiangsu Hengrui Medicine Co., Ltd.'s Docetaxel) in China
  • 3.4 Shenzhen Wanle Pharmaceutical Co.,Ltd.
    • 3.4.1 Enterprise Profile
    • 3.4.2 Sales of Xichun (Shenzhen Wanle Pharmaceutical Co.,Ltd.'s Docetaxel) in China
  • 3.5 Sichuan Huiyu Pharmaceutical Co., Ltd.
    • 3.5.1 Enterprise Profile
    • 3.5.2 Sales of Huiyu (Sichuan Huiyu Pharmaceutical Co., Ltd.'s Docetaxel) in China
  • 3.6 Yangtze River Pharmaceutical Group Co.,Ltd.
    • 3.6.1 Enterprise Profile
    • 3.6.2 Sales of Tianlun (Yangtze River Pharmaceutical Group Co.,Ltd.'s Docetaxel) in China

4 Prices of Docetaxel for Different Manufacturers in China, 2020-2021

  • 4.1 Aventis Pharma SA (TAXOTERE)
  • 4.2 Jiangsu Hengrui Medicine Co., Ltd. (Aisu)
  • 4.3 Shenzhen Wanle Pharmaceutical Co., Ltd. (Xichun)
  • 4.4 Sichuan Huiyu Pharmaceutical Co., Ltd. (Huiyu)
  • 4.5 Yangtze River Pharmaceutical Group Co.,Ltd. (Tianlun)

5 Prospect of Chinese Docetaxel Market, 2021-2025

  • 5.1 Influential Factors of Chinese Docetaxel Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Docetaxel Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Docetaxel Injection Registration in China
  • Chart Sales Value of Docetaxel Injection over the World
  • Chart Sales Value of Docetaxel Injection in China, 2016-2020
  • Chart Sales Value of Docetaxel Injection in China by Region, 2016-2020
  • Chart Sales Volume of Docetaxel Injection in China, 2016-2020
  • Chart Sales Volume of Docetaxel Injection in China by Region, 2016-2020
  • Chart Market Share by Sales Value of Top Docetaxel Injection Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of TAXOTERE in China, 2016-2020
  • Chart Sales Value and Volume of Aisu in China, 2016-2020
  • Chart Sales Value and Volume of Xichun in China, 2016-2020
  • Chart Sales Value and Volume of Huiyu in China, 2016-2020
  • Chart Sales Value and Volume of Tianlun in China, 2016-2020
  • Chart Referential Prices of TAXOTERE in China by Region, 2020-2021
  • Chart Referential Prices of Aisu in China by Region, 2020-2021
  • Chart Referential Prices of Xichun in China by Region, 2020-2021
  • Chart Referential Prices of Huiyu in China by Region, 2020-2021
  • Chart Referential Prices of Tianlun in China by Region, 2020-2021
  • Chart Forecast on Sales Value of Docetaxel Injection in China, 2021-2025
  • Chart Forecast on Sales Volume of Docetaxel Injection in China, 2021-2025